Plant Name: Cedronella canariensis
Taxonomic Information:
Plant ID: NPO14449
Plant Latin Name: Cedronella canariensis
Taxonomy Genus: Cedronella
Taxonomy Family: Lamiaceae
Plant External Links:
NCBI TaxonomyDB:
260595
Plant-of-the-World-Online:
445603-1
Used in Medicines:
Unknown.
Geographical Distribution:
United States; New Zealand; Portugal; South Africa
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| ACHE; | |
| PIM1; MET; FLT3; CDK1; AXL; KDR; IGF1R; AURKB; | |
| CA2; CA1; CA12; CA14; CA7; CA4; | |
| ALOX12; HSD17B10; NOX4; POLB; | |
| KDM4E; | |
| MMP9; MMP1; MMP12; MMP2; | |
| HIF1A; NFKB1; | |
| FUT7; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.061E-14 | 1.102E-09 | CA1, CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.912E-11 | 5.017E-07 | CA1, CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.762E-09 | 8.592E-06 | CA1, CA12, CA2, CA4, CA7 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.412E-07 | 2.388E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 6.864E-07 | 5.154E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 7.287E-07 | 5.289E-04 | ALOX12, CDK1, FLT3, HIF1A, IGF1R, KDR, MMP12, MMP2, MMP9, PIM1 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 3.431E-06 | 1.756E-03 | MMP1, MMP12, MMP2, MMP9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.467E-06 | 1.756E-03 | CA1, CA12, CA2, CA4, CA7, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.471E-06 | 2.864E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 7.497E-06 | 2.864E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.088E-05 | 3.644E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.401E-05 | 4.124E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 2.066E-05 | 5.555E-03 | ALOX12, CYP1A1, CYP1B1, NOX4 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 3.088E-05 | 7.911E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
| MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 3.313E-05 | 8.198E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 3.428E-05 | 8.386E-03 | AXL, FLT3, HIF1A, POLB |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 3.724E-05 | 8.911E-03 | CA1, CA2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.350E-22 | 4.417E-20 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA4, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.821E-11 | 1.712E-09 | CAMK2B, SRC, MMP2, PIK3R1, HIF1A, MMP9, PTK2, IGF1R, KDR, AKT1, MAPK1, TP53, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 7.922E-10 | 4.679E-08 | GSK3B, FLT3, MMP1, DAPK1, MMP2, PIK3R1, HIF1A, MMP9, NFKB1, PTK2, IGF1R, AKT1, MAPK1, MET, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.955E-10 | 4.679E-08 | MMP1, DAPK1, SRC, MMP2, MAPK1, MMP9, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.736E-08 | 6.526E-07 | HPGD, FLT3, MMP3, TP53, MPO, MMP9, MET, NFKB1, PTK2, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 5.772E-08 | 1.550E-06 | GSK3B, SRC, AKT1, MAPK1, PIK3R1, NFKB1, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.475E-08 | 1.089E-06 | FLT3, AKT1, MAPK1, PIK3R1, TP53, MET, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.489E-07 | 3.499E-06 | ALOX5, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.525E-07 | 4.476E-06 | GSK3B, AKT1, MAPK1, PIK3R1, TP53, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.158E-07 | 4.476E-06 | CAMK2B, GSK3B, SRC, AKT1, MAPK1, PIK3R1, PTK2 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 4.033E-07 | 5.416E-06 | CASP7, PARP1, LMNA, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.308E-07 | 5.183E-06 | FLT3, PIM1, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 5.557E-07 | 6.145E-06 | SRC, AKT1, MAPK1, STAT6, PIK3R1, TP53, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 8.113E-07 | 7.263E-06 | GSK3B, KDR, AKT1, MAPK1, PIK3R1, PKN1, TP53, MET, PTK2, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 5.245E-07 | 6.145E-06 | SRC, MMP2, AKT1, MAPK1, PIK3R1, MMP9, ESR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 4.984E-07 | 6.145E-06 | SRC, KDR, AKT1, MAPK1, PIK3R1, PTK2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 6.073E-07 | 6.343E-06 | GSK3B, SRC, KDR, AKT1, MAPK1, PIK3R1, MET, PTK2, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 7.299E-07 | 6.861E-06 | CAMK2B, AKT1, MAPK1, PIK3R1, TP53, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 6.871E-07 | 6.799E-06 | CAMK2B, AKT1, MAPK1, PIK3R1, HIF1A, NFKB1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.675E-07 | 5.315E-06 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.074E-06 | 9.174E-06 | CASP7, MMP3, AKT1, MAPK1, PIK3R1, MMP9, NFKB1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.660E-06 | 1.200E-05 | PLA2G1B, MAOA, GAA, ALOX15, AKR1B1, ALOX12, PYGL, CYP3A4, CYP19A1, HSD17B10, CYP2C8, FUT7, ALOX5, HSD17B2, CYP1A2, ALDH1A1, CYP1A1, CD38, ALPI, XDH |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.213E-06 | 9.684E-06 | APP, CYP2C8, MAOA, ALOX5, ALOX15, MAPK1, ALOX12 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.619E-07 | 4.476E-06 | CYP2C8, PLA2G1B, CYP1A2, ALOX15, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.236E-06 | 9.684E-06 | AKT1, MAPK1, PIK3R1, TP53, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.723E-06 | 1.200E-05 | GSK3B, SRC, AKT1, MAPK1, PIK3R1, TP53, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.929E-06 | 1.295E-05 | CAMK2B, GSK3B, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 3.573E-06 | 2.317E-05 | GSK3B, CXCR1, SRC, AKT1, MAPK1, PIK3R1, NFKB1, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 6.314E-06 | 3.829E-05 | GSK3B, CSNK2A1, CDK1, AKT1, CD38, PIK3R1, TP53, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.580E-06 | 1.189E-05 | PTPN1, CSNK2A1, SRC, MAPK1, MET, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 9.733E-06 | 5.545E-05 | MMP2, PIM1, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.478E-05 | 7.660E-05 | PLA2G1B, KDR, AKT1, MAPK1, PIK3R1, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.507E-05 | 7.660E-05 | PTPN1, GSK3B, AKT1, PIK3R1, PYGL, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 5.248E-06 | 3.288E-05 | GSK3B, AKT1, MAPK1, PIK3R1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 7.595E-06 | 4.462E-05 | ALK, AKT1, MAPK1, PIK3R1, TP53 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 1.773E-05 | 8.130E-05 | BACE1, APP, GSK3B, CASP7, MAPK1, MAPT, HSD17B10 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.605E-05 | 1.166E-04 | ABCC1, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.257E-05 | 6.754E-05 | GSK3B, AKT1, MAPK1, PIK3R1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.257E-05 | 6.754E-05 | CYP2C8, PLA2G1B, ALOX5, ALOX15, ALOX12 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 6.320E-05 | 2.330E-04 | POLB, SRC, CDK1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 4.649E-05 | 1.900E-04 | GSK3B, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.710E-05 | 8.038E-05 | AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 5.267E-05 | 2.063E-04 | GSK3B, CSNK2A1, AKT1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 7.576E-05 | 2.739E-04 | SRC, KDR, AKT1, MAPK1, PIK3R1, MET, IGF1R |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.799E-05 | 1.196E-04 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 9.909E-05 | 3.450E-04 | ABCC1, PIM1, CYP1B1, MAPK1, TP53, MMP9, MET, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 5.949E-05 | 2.282E-04 | PTPN1, GSK3B, AKT1, MAPK1, PIK3R1, PYGL |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.710E-05 | 8.038E-05 | AKT1, MAPK1, PIK3R1, MET, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.799E-05 | 1.196E-04 | AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.587E-05 | 7.850E-05 | CYP2C8, CYP1A2, ALDH1A1, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 2.107E-04 | 6.715E-04 | GSK3B, CASP1, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.150E-04 | 3.931E-04 | CDK1, AKT1, MAPK1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 9.439E-05 | 3.348E-04 | AKT1, PIK3R1, TP53, NFKB1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 2.065E-04 | 6.695E-04 | CAMK2B, ACHE, AKT1, MAPK1, PIK3R1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 6.174E-05 | 2.322E-04 | AKT1, PIK3R1, TP53, NFKB1, PTK2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.522E-04 | 5.110E-04 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.912E-05 | 1.965E-04 | CYP2C8, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.745E-04 | 8.461E-04 | ALOX5, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 4.142E-04 | 1.217E-03 | CAMK2B, GSK3B, MAOA, AKT1, DRD4 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 8.468E-04 | 2.274E-03 | GSK3B, CASP7, AKT1, PIK3R1, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 6.417E-04 | 1.774E-03 | GSK3B, AKT1, MAPK1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 1.037E-03 | 2.709E-03 | CAMK2B, SRC, CD38, MAPK1, PIK3R1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 1.614E-03 | 3.992E-03 | POLB, GSK3B, AKT1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.327E-03 | 3.372E-03 | AKT1, MAPK1, PIK3R1, ADRA2C, ADRA2A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 1.758E-03 | 4.212E-03 | CAMK2B, SRC, AKT1, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.325E-03 | 3.372E-03 | CAMK2B, SRC, ALOX12, PIK3R1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.006E-03 | 2.665E-03 | CAMK2B, SRC, MMP2, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 1.482E-03 | 3.714E-03 | AKT1, MAPK1, PIK3R1, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.852E-03 | 6.461E-03 | CAMK2B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 2.059E-04 | 6.695E-04 | AKT1, MAPK1, PIK3R1, HIF1A |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.770E-03 | 4.212E-03 | AKT1, MAPK1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.650E-03 | 4.029E-03 | AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 2.950E-03 | 6.603E-03 | SRC, AKT1, MAPK1, PIK3R1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 2.616E-03 | 6.071E-03 | MMP2, PIK3R1, MMP9, PTK2 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 3.038E-03 | 6.720E-03 | CAMK2B, CDK1, MAPK1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 5.635E-04 | 1.581E-03 | SRC, PIK3R1, MET, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 8.144E-04 | 2.219E-03 | CASP1, MAPK1, PKN1, NFKB1 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.912E-03 | 8.264E-03 | AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 3.408E-03 | 7.451E-03 | GSK3B, MAPK1, MET, PTK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 4.019E-03 | 8.395E-03 | AKT1, MAPK1, PIK3R1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.338E-04 | 1.012E-03 | CXCR1, SRC, MET, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.380E-04 | 1.267E-03 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 4.855E-04 | 1.383E-03 | CASP7, CASP1, MAPK1, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.531E-04 | 1.054E-03 | CYP2C8, MAOA, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.156E-05 | 1.736E-04 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 4.412E-03 | 9.115E-03 | AKT1, MAPK1, PIK3R1 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.720E-03 | 8.038E-03 | AKT1, PIK3R1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 3.886E-03 | 8.264E-03 | SRC, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.677E-03 | 6.137E-03 | CASP1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 2.417E-03 | 5.680E-03 | CASP7, CASP1, NFKB1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.306E-04 | 7.226E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MMP9; MMP2; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; HIF1A; MMP9; MMP2; CA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; CA1; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
